Literature DB >> 14578720

Respiratory artefact causing malpositioning of liver dome lesion in right lower lung.

Ismet Sarikaya1, Henry W D Yeung, Yusuf Erdi, Steven M Larson.   

Abstract

The new combined positron emission (PET)/computed tomographic (CT) scanners have many advantages over PET scanners alone. However, physicians must be aware of the potential artefacts observed in PET/CT scanners. A body PET/CT was performed on an 81-year-old man with colorectal cancer. The CT-based, attenuation-corrected PET image showed a right lower lung lesion. However, there was no lung lesion on the transmission CT image. Nonattenuation-corrected PET, and rod source-based, attenuation-corrected PET images demonstrated focal uptake in the dome of the liver. Dedicated CT with intravenous contrast confirmed that the lesion was in the liver dome and not in the right lower lung. The liver lesion was misplaced to the right lower lung in the CT-based, attenuation-corrected PET image because of a respiratory artefact. To overcome this respiration artefact the authors suggest a routine review of the nonattenuation-corrected PET images, particularly when evaluating liver dome and lower lung lesions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578720     DOI: 10.1097/01.rlu.0000093095.28642.2b

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  9 in total

1.  The impact of audio-visual biofeedback on 4D PET images: results of a phantom study.

Authors:  Jaewon Yang; Tokihiro Yamamoto; Byungchul Cho; Youngho Seo; Paul J Keall
Journal:  Med Phys       Date:  2012-02       Impact factor: 4.071

2.  Respiratory-induced errors in tumor quantification and delineation in CT attenuation-corrected PET images: effects of tumor size, tumor location, and respiratory trace: a simulation study using the 4D XCAT phantom.

Authors:  Parham Geramifar; Mojtaba Shamsaie Zafarghandi; Pardis Ghafarian; Arman Rahmim; Mohammad Reza Ay
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

3.  Respiratory motion handling is mandatory to accomplish the high-resolution PET destiny.

Authors:  Doumit Daou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-12       Impact factor: 9.236

4.  Respiratory motion artefact in the liver dome on FDG PET/CT: comparison of attenuation correction with CT and a caesium external source.

Authors:  Dimitri Papathanassiou; Stéphanie Becker; Roland Amir; Benoît Menéroux; Jean-Claude Liehn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-08-31       Impact factor: 9.236

5.  The impact of data-driven respiratory gating in clinical F-18 FDG PET/CT: comparison of free breathing and deep-expiration breath-hold CT protocol.

Authors:  Seo Young Kang; Byung Seok Moon; Hye Ok Kim; Hai-Jeon Yoon; Bom Sahn Kim
Journal:  Ann Nucl Med       Date:  2021-01-15       Impact factor: 2.668

6.  Joint correction of respiratory motion artifact and partial volume effect in lung/thoracic PET/CT imaging.

Authors:  Guoping Chang; Tingting Chang; Tinsu Pan; John W Clark; Osama R Mawlawi
Journal:  Med Phys       Date:  2010-12       Impact factor: 4.071

7.  Implementation of an automated respiratory amplitude gating technique for PET/CT: clinical evaluation.

Authors:  Guoping Chang; Tingting Chang; Tinsu Pan; John W Clark; Osama R Mawlawi
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

Review 8.  Attenuation-corrected vs. nonattenuation-corrected 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in oncology: a systematic review.

Authors:  Urvi Joshi; Pieter G H M Raijmakers; Ingrid I Riphagen; Gerrit J J Teule; Arthur van Lingen; Otto S Hoekstra
Journal:  Mol Imaging Biol       Date:  2007 May-Jun       Impact factor: 3.488

9.  Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to 18F-FDG-PET/CT.

Authors:  Donatienne Van Weehaeghe; Olivier Gheysens; Vincent Vandecaveye; Patrick Schöffski; Koen Van Laere; Christophe M Deroose
Journal:  BMC Cancer       Date:  2018-03-05       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.